US · ALXO · BIOTECHNOLOGY
ALX Oncology Holdings Inc. (ALXO) intrinsic value and stock valuation
$1.06as of 2026-11-21 · Mkt cap 258.36M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ALX Oncology Holdings Inc. DCF and intrinsic value
InvestorsCraft values ALXO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALXO’s statements →
ALX Oncology Holdings Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-104.02M | -$-142.47M | -$-170.28M | -$-127.44M | -$-83.56M |
| Net income | -$-101.69M | -$-134.85M | -$-160.81M | -$-123.48M | -$-83.46M |
| EPSd | -$-1.9M | -$-2.58M | -$-3.74M | -$-3.03M | -$-2.07M |
| Operating cash flow | -$-84.14M | -$-121.91M | -$-130.36M | -$-89.22M | -$-68.1M |
| Capital expenditure | -$-210K | -$-450K | -$-1.27M | -$-1.43M | -$-4.92M |
| Free cash flow | -$-84.35M | -$-122.36M | -$-131.64M | -$-90.65M | -$-73.02M |
| Total assets | $59.1M | $147.8M | $242.6M | $306.5M | $380.2M |
| Total debt | $5.22M | $17M | $17.2M | $10.4M | $740K |
| Net debt | -$-11.16M | -$-590K | -$-5.21M | -$-38.39M | -$-362.93M |
| Total equity | $26M | $113.6M | $189.7M | $263.5M | $363.1M |
| Cash and short-term investments | $44.8M | $127.8M | $182.7M | $266.2M | $363.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $77M | $116.4M | $141.8M | $98.4M | $60.2M |
| Selling, general and administrative expenses | $23.9M | $26.1M | $28.5M | $29M | $23.4M |
| Other expenses | $3.17M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $104M | $142.5M | $170.3M | $127.4M | $83.6M |
| Cost and expenses | $104M | $142.5M | $170.3M | $127.4M | $83.6M |
| Interest income | $3.96M | $9.37M | $10.7M | $4.28M | $0.00 |
| Interest expense | $1.6M | $1.73M | $1.56M | $240K | $10K |
| Depreciation and amortization | $710K | $870K | $840K | $340K | $50K |
| Ebitda | -$-99.39M | -$-132.25M | -$-158.4M | -$-122.84M | -$-83.42M |
| Operating income | -$-104.02M | -$-142.47M | -$-170.28M | -$-127.44M | -$-83.56M |
| Total other income/expenses, net | $2.33M | $7.62M | $9.47M | $4.02M | $70K |
| Income before tax | -$-101.69M | -$-134.85M | -$-160.81M | -$-123.42M | -$-83.48M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $60K | -$-20K |
| Net income | -$-101.69M | -$-134.85M | -$-160.81M | -$-123.48M | -$-83.46M |
| Weighted average shares outstanding | $53.7M | $52.2M | $43M | $40.7M | $40.3M |
| Weighted average diluted shares outstanding | $53.7M | $52.2M | $43M | $40.7M | $40.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $44.8M | $127.8M | $182.7M | $266.2M | $363.7M |
| Net receivables | $300K | $890K | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $50.7M | $134.4M | $188.7M | $271M | $367M |
| Property, plant and equipment, net | $1.2M | $9.63M | $10.8M | $9.81M | $3.47M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $3.49M | $3.52M | $35.4M | $16.7M | $0.00 |
| Total non-current assets | $8.32M | $13.4M | $53.9M | $35.5M | $13.2M |
| Total assets | $59.1M | $147.8M | $242.6M | $306.5M | $380.2M |
| Accounts payable | $4.91M | $4.5M | $8.59M | $8.07M | $3.76M |
| Short-term debt | $5.22M | $2.35M | $1.57M | $1.04M | $740K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $24.6M | $18.5M | $36M | $28.3M | $15.3M |
| Long-term debt | $0.00 | $14.6M | $15.6M | $9.39M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $8.51M | $15.7M | $16.8M | $14.7M | $1.84M |
| Capital lease obligations | $0.00 | $7.07M | $7.56M | $1.04M | $740K |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43M | $17.1M |
| Common stock | $50K | $50K | $50K | $40K | $40K |
| Retained earnings | -$-722.82M | -$-621.12M | -$-486.27M | -$-325.47M | -$-201.99M |
| Accumulated other comprehensive income (loss) | $30K | $280K | $260K | -$-840K | -$0.00 |
| Total equity | $26M | $113.6M | $189.7M | $263.5M | $363.1M |
| Total investments | $31.9M | $113.7M | $195.7M | $234.1M | $0.00 |
| Total debt | $5.22M | $17M | $17.2M | $10.4M | $740K |
| Net debt | -$-11.16M | -$-590K | -$-5.21M | -$-38.39M | -$-362.93M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-101.69M | -$-134.85M | -$-160.81M | -$-123.48M | -$-83.46M |
| Depreciation and amortization | $710K | $870K | $840K | $340K | $50K |
| Stock-based compensation | $12.6M | $27.1M | $26.3M | $23.8M | $13.9M |
| Change in working capital | $340K | -$-12.43M | $8.3M | $9.85M | -$-4.03M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $420K | -$-4.02M | $460K | $4.51M | $3.29M |
| Net cash provided by operating activities | -$-84.14M | -$-121.91M | -$-130.36M | -$-89.22M | -$-68.1M |
| Investments in property, plant and equipment | -$-210K | -$-450K | -$-1.27M | -$-1.43M | -$-670K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $230K | $0.00 |
| Net cash used for investing activities | $82.6M | $86.3M | $44.7M | -$-235.42M | -$-4.92M |
| Common stock issued | $1.73M | $31.6M | $58.9M | $900K | $2.75M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $360K | $30.8M | $59.3M | $9.86M | $2.47M |
| Net change in cash | -$-1.19M | -$-4.84M | -$-26.42M | -$-314.78M | -$-70.55M |
| Cash at end of period | $16.4M | $17.6M | $22.5M | $48.9M | $363.7M |
| Operating cash flow | -$-84.14M | -$-121.91M | -$-130.36M | -$-89.22M | -$-68.1M |
| Capital expenditure | -$-210K | -$-450K | -$-1.27M | -$-1.43M | -$-4.92M |
| Free cash flow | -$-84.35M | -$-122.36M | -$-131.64M | -$-90.65M | -$-73.02M |
Line items
Line items
Line items
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- CEO
- Jason Lettmann
- Employees
- 43
- Beta
- 0.43
Explore
Frequently asked questions
What is the intrinsic value of ALX Oncology Holdings Inc. (ALXO)?
InvestorsCraft does not currently publish an intrinsic value for ALXO. How the IC value is calculated.
Is ALXO undervalued?
InvestorsCraft does not publish an undervaluation signal for ALXO at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.